Podcast discusses measuring aging and testing anti-aging drugs
In this podcast description, Dr. Nir Barzilai argues that medicine lacks a reliable way to tell whether an intervention changes the biology driving age-related disease, and discusses TAME, FAST and drugs studied as gerotherapeutics. [1]
Automatic summary · not editorially reviewed
The key findings
The description says medicine still lacks a reliable way to tell whether an intervention changes the biology driving age-related disease. [1]
The description says TAME was designed to test metformin as an anti-aging drug and to make aging an FDA endpoint, but it failed to get off the ground. [1]
The description says FAST searches existing clinical trials for biomarkers that change when an intervention affects aging biology. [1]
The source at a glance
- Study type / format
- Video description of a podcast episode
- Population / context
- Not specified in the description; the discussion concerns aging biology and people studied in aging research.
- Summary based on
- Creator description
- Original publication
- September 10, 2026
Barzilai's measurement problem in the description
According to the description, aging science has become better at describing who appears to age faster or slower. What medicine still lacks, Dr. Nir Barzilai argues, is a reliable feedback loop: a way to tell whether something we do actually changes the biology that drives age-related disease. He proposes measuring where you are, intervening, measuring again and learning what works. The description also lists topics such as whether aging needs continuous monitoring or a few checks a year.
Supporting source [1]
TAME, FAST and drugs studied as gerotherapeutics
The description says TAME was designed to test metformin as an anti-aging drug and to convince the FDA to treat aging itself as an endpoint, and that it failed to get off the ground. It also says metformin, SGLT2 inhibitors, GLP-1 agonists and some osteoporosis drugs are being studied as potential gerotherapeutics, or anti-aging drugs. FAST is described as searching existing clinical trials for biomarkers that change when an intervention affects aging biology. These are described research efforts, not established treatments.
Supporting source [1]
Centenarians and hallmarks in the episode list
The episode list says centenarians reveal something about living longer and spending less time sick, and that changing one hallmark of aging can affect several others. It also raises whether aging should be called a disease and why the species may have a ceiling around 115. The description does not report study designs, sample sizes or results for these points, so they remain topics raised rather than demonstrated findings.
Supporting source [1]
How to interpret this
This explainer is based only on the video description; the video and transcript were not reviewed. The description lists topics and links but reports no study designs, sample sizes, follow-up or results, so no findings can be confirmed.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Levels | Health, Metabolism & Human Performance · youtube.com · September 10, 2026